ABOUT

MISSION STATEMENT:

Affinity Bio Partners (ABP) and its affiliates ensure that on a global basis that clinical research is performed safely, ethically, with high-quality so that subjects can benefit from the development of new  and novel treatments and therapies. Our partners will find that ABP is dedicated to helping their clients bring efficiency, innovation and value to the clinical research process while staying on budget and pushing timelines ahead as aggressively as possible.

About ABP:

Founded in November 2014, in a transition from Christina DiArcangelo Puller's previous company Armonia Clinical Research (first formed in 2009), ABP represents the world’s leading cutting-edge Clinical Research Organization (CRO).  Affinity Bio Partners LLC endeavors to provide integral enterprise-wide solutions that facilitate the development of drugs, biologics, natraceuticals and medical devices. ABP provides services such as, but not limited too:

  • Groundbreaking Medical Marijuana and Cannabinoid Clinical Research activities

  • Clinical Research Operations and Product Marketing

  • Enterprise-wide Strategic Planning Solutions

  • Enterprise-wide Governance Solutions

  • Asset Procurement and Staffing Solutions

  • Advance clinical outsourcing to improve the quality, efficiency and safety of biomedical research.

  • Conducting clinical trials in domestic and international settings while ensuring the safety of research participants.

  • Strengthen public understanding and confidence in clinical research, highlighting CRO expertise in all aspects of the clinical research enterprise.

Affinity Bio Partners LLC and Christina DiArcangelo Puller have been leading voices for safe and ethical clinical trials while working with stakeholders globally to promote a better and more efficient clinical trial process.  Affinity Bio Partners LLC maintains an unwavering dedication to bringing efficiency, safety, innovation and value to the clinical research process.  It is equally as critical to our organization that we highlight for our partners the differentiation between the value and services ABP provides as opposed to other CROs in the market.  Rather than operate in the same fashion that traditional large CRO conglomerates operate their clinical trials, the ABP difference is that our clients truly matter and we believe in forming valuable cost-effective partnerships that facilitate the development of new medicines and new treatments that benefit millions of subjects worldwide.

THE AFFINITY BIO PARTNERS  CEO
party headshot.JPG
Christina DiArcangelo  

CEO - Affinity Bio Partners, Affinity Patient Advocacy, AI Health Outcomes, CannaBot, Christina DiArcangelo Brand, Chief R&D Officer, Spectral Analytics, Inc., CEO, Spectral Analytics Precision Tele-Monitoring

 

An entrepreneur and CEO with more than two decades of experience in the medical cannabis, biotechnology, pharmaceutical, nutraceutical, and medical device industries, Christina’s dedication to revolutionizing patient care is unprecedented. Through her roles as CEO, Spectral Analytics Precision Tele-Monitoring, Founder and CEO of Affinity Bio Partners, Board President and CEO of Affinity Patient Advocacy, and CEO & Co-Founder of AI Health Outcomes, Christina has been involved with revolutionary projects and global clinical studies that positively impact patients.

Christina was a participant in Season 2 of the “Four Days to Save the World” TV Series that will be released on Earth Day 2022.

As a clinical research pioneer, contracts negotiator, Opinion Columnist for CEO WorldBiz and has a Podcast, I am Christina DiArcangelo, she has utilized the tools at her disposal to champion patient care and provide best-in-class patient advocacy services. For Christina, patient care comes first.

As an active Bahai’ and mother to her one son, Christian, she believes that listening, learning, and growing are everyday values that can change the world by impacting our own hearts, homes, and communities.